Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Mainz Biomed N.V. - Ordinary Shares
(NQ:
MYNZ
)
0.3590
+0.0118 (+3.40%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Mainz Biomed N.V. - Ordinary Shares
< Previous
1
2
3
4
5
6
7
8
9
Next >
Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment
March 19, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options
March 18, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations
March 12, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
The Latest Analyst Ratings for Mainz Biomed
November 20, 2023
Via
Benzinga
Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic
March 05, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
Gynecology Plays A Pivotal Role In Colorectal and Endometrial Cancer Screening
February 28, 2024
When it comes to cancer, one cannot overestimate the importance of early detection. Especially when it comes to colorectal and endometrial cancer that even big pharma companies don’t have a good track...
Via
Benzinga
Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community
February 27, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
Outdoing Cancer Requires Pharma To Go Beyond Merely Revolutionizing Existing Treatment
February 22, 2024
Pfizer Inc (NYSE: PFE) is among the many pharmaceutical companies that turned to oncology in response to sinking demand for its COVID-19 products and near patent expiration dates for its several...
Via
Benzinga
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert®
February 22, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy
February 21, 2024
Partnership Brings Pioneering Approach to Incorporating Advanced Colorectal Cancer Detection Into Country’s Healthcare System
From
Mainz BioMed NV
Via
GlobeNewswire
2024 Promises To Bring Pharmaceutical Breakthroughs On The Oncology Front
February 07, 2024
On Thursday, Merck & Co Inc (NYSE: MRK) topped estimates with its fourth quarter revenue and adjusted earnings fueled by its blockbuster cancer drug Keytruda, along with HPV prevention vaccine...
Via
Benzinga
Mainz Biomed Establishes Physician-Led Laboratory Expanding Service Offering for Privately Insured Patients in Germany
February 06, 2024
Company opens own physician-led laboratory, ‘European Oncology Lab’ (EOL), thereby offering ColoAlert® as a laboratory medical service directly to physicians and patients
From
Mainz BioMed NV
Via
GlobeNewswire
2 Million Cancer Diagnoses And 600,000 Cancer Deaths Expected In 2024 – Prevention Is Key To Treatment, And Mainz Biomed Is Leading The Charge
February 02, 2024
--News Direct--
Via
News Direct
Topics
Death
Exposures
Death
Pfizer Surprises With Profit But Revolutionizing Cancer Treatment Is Its Best Chance Of Getting Back In The Saddle
February 01, 2024
On Tuesday, Pfizer Inc (NYSE: PFE) reported mixed results for its fourth quarter. Last year, Pfizer has responded to concerns related to its COVID-19 products being the rearview mirror with a...
Via
Benzinga
Exposures
COVID-19
2 Million Cancer Diagnoses And 600,000 Cancer Deaths Expected In 2024 – Prevention Is Key To Treatment, And Mainz Biomed Is Leading The Charge
February 01, 2024
The global population is experiencing a scary increase in colorectal cancer, especially among young people. Colorectal cancer (CRC) diagnoses have been steadily rising since the 1990s; in 1995 the...
Via
Benzinga
Topics
Death
Exposures
Death
Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium
January 11, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
2024 Marks a New Era Of Pharmaceutical Innovation
January 09, 2024
With Covid-19 finally fading into history, the Covid-19 heroes, namely Moderna Inc (NASDAQ: MRNA) and Pfizer Inc (NYSE: PFE) were forced to redefine their business focus last year, and so, they turned...
Via
Benzinga
Exposures
COVID-19
Mainz Biomed Provides Year-End Corporate Review 2023
January 09, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
2023 Will Go Down As The Year Pharma Showed Its Determination To Beat Cancer
December 29, 2023
During the last week of 2023, AstraZeneca PLC (NASDAQ: AZN) agreed to acquire Chinese cancer therapy developer Gracell Biotechnologies Inc.
Via
Benzinga
Is This BioTech Play Severely Undervalued? BioTech Shares Promising Results From Colorectal Study
December 19, 2023
Via
Benzinga
Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees
December 19, 2023
Hermann Bantleon GmbH (“Bantleon), Shareholder of German AVIA, will Offer the ColoAlert® At-Home Screening Test to Employees Across All Three of Their German Locations, Namely Ulm, Ulm-Nord, and...
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in Poland
December 12, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
December 05, 2023
Shares of Daktronics, Inc. (NASDAQ: DAKT) moved lower during Tuesday’s session following weak quarterly results.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
December 05, 2023
Via
Benzinga
While Pfizer Faced A Setback, Altimmune, Roche And Mainz Biomed Advanced in The Battle Against Obesity And Colorectal Cancer
December 05, 2023
Obesity has been linked to development of a range of diseases and unfortunately, cancer. More specifically, the National Cancer Institute estimated that colorectal cancer is 1.3 times more likely in...
Via
Benzinga
Mainz Biomed Reports Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA Biomarkers
December 05, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed’s Presentation at the 35th Annual Piper Sandler Healthcare Conference to be Made Available via Webcast
November 29, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed to Present at the 35th Annual Piper Sandler Healthcare Conference
November 20, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
November 16, 2023
Via
Benzinga
Mainz Biomed Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 16, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.